Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

News, features, and commentary about cancer-related issues ...

The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet ...

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some of the most challenging diagnoses in modern medicine. From the introduction ...

If AML stops responding to conventional intensive chemotherapy or comes back, the chances of a long-term cure decrease significantly," explains Prof ...

T-cell therapy is based on engineered immune cells that find and destroy cancer cells. However, sometimes these cells also attack healthy tissues, causing side effects. An international team of ...

SELLAS Life Sciences stock jumps over 200% in six months as cancer trial updates boost momentum and short interest tops 27%.

Roche and AbbVie’s Venclexta approved in CLL Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with ...

Baystreet.ca News Commentary — The global oncology and cancer drugs market, valued at $167 billion in 2023, is projected to reach $335.2 billion by 2033 at a compound annual growth ...